PTU-289 Embedding pharmaceutical care into the multidisciplinary team

Introduction Pharmacists traditionally do not get involved in the long-term management of patients with chronic disease. This service development aimed to integrate pharmacy-lead IBD medication optimisation into the IBD Multi Disciplinary Team (MDT). We report our experience of extending our special...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Gut 2015-06, Vol.64 (Suppl 1), p.A187-A188
Hauptverfasser: Jones, A St. Clair, Smith, MA
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page A188
container_issue Suppl 1
container_start_page A187
container_title Gut
container_volume 64
creator Jones, A St. Clair
Smith, MA
description Introduction Pharmacists traditionally do not get involved in the long-term management of patients with chronic disease. This service development aimed to integrate pharmacy-lead IBD medication optimisation into the IBD Multi Disciplinary Team (MDT). We report our experience of extending our specialist pharmacist's remit. Method A weekly pharmacist outpatient clinic was established, to initiate immunomodulating drugs and undertake biochemical monitoring. The pharmacist optimised therapy according to blood levels, adverse drug reactions (ADRs) and concordance. Strategic and operational management of the biologics infusion clinic was transferred to the pharmacist. A new blood and therapeutic drug monitoring (TDM) service for immunomodulators and biologics was introduced to optimise therapy decisions. The rapid access (helpline) service was reviewed to see whether the pharmacist could add value. The pharmacist facilitated MDT-approved pathways to initiate and review immunomodulators. A workload and prescription audit was conducted over four months with financial impact assessment. Patient and anonymous colleague feedback was sought. Results In the four months analysed, 14 pharmacist clinics were held, serving 138 patients. 382 patients had blood monitoring, ensuring clinical governance. The biologics infusion clinic expanded to include a cross-speciality services. 65 patients had their immunosupressant therapy adjusted in the TDM service. The pharmacist is gatekeeper for testing and is responsible for optimising therapies (as a non-medical prescriber). The advice sought from the rapid access service was primarily nurse-orientated and the service remains nurse-lead, with pharmacist deputising to maximise resources. In 4 months 142 of 1032 queries were answered by the pharmacist. The MDT reviewed 42 patients on biologics according to the new pathways. The TDM service resulted in a minimum of £60,000 savings for the health economy. 6 of 6 peer-assessors returned overwhelmingly positive reviews of the service and patient feedback was fa. Conclusion Involving the pharmacist in all aspects of the long-term care of patients with IBD enhanced patient safety and standardised treatment and monitoring protocols, whilst individualising therapy. The focus of the MDT shifted to early medicines optimisation, realising considerable cost savings. Interprofessional relationships profited from working closely together / deputising for each other. Embedding pharmaceutical skills
doi_str_mv 10.1136/gutjnl-2015-309861.403
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2043387041</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2043387041</sourcerecordid><originalsourceid>FETCH-LOGICAL-c751-212c07ea8b996519c019e642c8819839ecc619601dfa574aee778951681fa1343</originalsourceid><addsrcrecordid>eNot0E1OwzAQBWALgUQpXAFFYu0yEzv-WaKqBaRKsChry3Wc1lX-cJwFt-EsnIygsJrN07ynj5B7hBUiE4_HMZ3bmuaABWWglcAVB3ZBFsiFoixX6pIsAFDSQnJ9TW6G4QwASmlckO37_oPmSv98b5qDL8vQHrP-ZGNjnR9TcLbOnI0-C23qsnTyWTPWKZRhcKGvQ2vjV5a8bW7JVWXrwd_93yXZbzf79QvdvT2_rp921MkCaY65A-mtOmgtCtQOUHvBc6cUasW0d06gFoBlZaet1nsplS5QKKwsMs6W5GF-28fuc_RDMudujO3UaHLgjCkJHKeUmFMudsMQfWX6GJppqkEwf2RmJjN_ZGYmMxMZ-wXE2WAb</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2043387041</pqid></control><display><type>article</type><title>PTU-289 Embedding pharmaceutical care into the multidisciplinary team</title><source>BMJ Journals - NESLi2</source><source>PubMed Central</source><creator>Jones, A St. Clair ; Smith, MA</creator><creatorcontrib>Jones, A St. Clair ; Smith, MA</creatorcontrib><description>Introduction Pharmacists traditionally do not get involved in the long-term management of patients with chronic disease. This service development aimed to integrate pharmacy-lead IBD medication optimisation into the IBD Multi Disciplinary Team (MDT). We report our experience of extending our specialist pharmacist's remit. Method A weekly pharmacist outpatient clinic was established, to initiate immunomodulating drugs and undertake biochemical monitoring. The pharmacist optimised therapy according to blood levels, adverse drug reactions (ADRs) and concordance. Strategic and operational management of the biologics infusion clinic was transferred to the pharmacist. A new blood and therapeutic drug monitoring (TDM) service for immunomodulators and biologics was introduced to optimise therapy decisions. The rapid access (helpline) service was reviewed to see whether the pharmacist could add value. The pharmacist facilitated MDT-approved pathways to initiate and review immunomodulators. A workload and prescription audit was conducted over four months with financial impact assessment. Patient and anonymous colleague feedback was sought. Results In the four months analysed, 14 pharmacist clinics were held, serving 138 patients. 382 patients had blood monitoring, ensuring clinical governance. The biologics infusion clinic expanded to include a cross-speciality services. 65 patients had their immunosupressant therapy adjusted in the TDM service. The pharmacist is gatekeeper for testing and is responsible for optimising therapies (as a non-medical prescriber). The advice sought from the rapid access service was primarily nurse-orientated and the service remains nurse-lead, with pharmacist deputising to maximise resources. In 4 months 142 of 1032 queries were answered by the pharmacist. The MDT reviewed 42 patients on biologics according to the new pathways. The TDM service resulted in a minimum of £60,000 savings for the health economy. 6 of 6 peer-assessors returned overwhelmingly positive reviews of the service and patient feedback was fa. Conclusion Involving the pharmacist in all aspects of the long-term care of patients with IBD enhanced patient safety and standardised treatment and monitoring protocols, whilst individualising therapy. The focus of the MDT shifted to early medicines optimisation, realising considerable cost savings. Interprofessional relationships profited from working closely together / deputising for each other. Embedding pharmaceutical skills into the multidisciplinary team influenced therapeutic decision making, ensuring that services incorporated good medicine management and medicine optimisation principles at conception to guarantee high-quality, compassionate care and strong governance. Disclosure of interest None Declared.</description><identifier>ISSN: 0017-5749</identifier><identifier>EISSN: 1468-3288</identifier><identifier>DOI: 10.1136/gutjnl-2015-309861.403</identifier><language>eng</language><publisher>London: BMJ Publishing Group LTD</publisher><subject>Blood levels ; Chronic illnesses ; Decision making ; Disease management ; Drug stores ; Embedding ; Feedback ; Immunomodulation ; Patients ; Therapeutic drug monitoring</subject><ispartof>Gut, 2015-06, Vol.64 (Suppl 1), p.A187-A188</ispartof><rights>Copyright: 2015 © 2015, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,3194,27923,27924</link.rule.ids></links><search><creatorcontrib>Jones, A St. Clair</creatorcontrib><creatorcontrib>Smith, MA</creatorcontrib><title>PTU-289 Embedding pharmaceutical care into the multidisciplinary team</title><title>Gut</title><description>Introduction Pharmacists traditionally do not get involved in the long-term management of patients with chronic disease. This service development aimed to integrate pharmacy-lead IBD medication optimisation into the IBD Multi Disciplinary Team (MDT). We report our experience of extending our specialist pharmacist's remit. Method A weekly pharmacist outpatient clinic was established, to initiate immunomodulating drugs and undertake biochemical monitoring. The pharmacist optimised therapy according to blood levels, adverse drug reactions (ADRs) and concordance. Strategic and operational management of the biologics infusion clinic was transferred to the pharmacist. A new blood and therapeutic drug monitoring (TDM) service for immunomodulators and biologics was introduced to optimise therapy decisions. The rapid access (helpline) service was reviewed to see whether the pharmacist could add value. The pharmacist facilitated MDT-approved pathways to initiate and review immunomodulators. A workload and prescription audit was conducted over four months with financial impact assessment. Patient and anonymous colleague feedback was sought. Results In the four months analysed, 14 pharmacist clinics were held, serving 138 patients. 382 patients had blood monitoring, ensuring clinical governance. The biologics infusion clinic expanded to include a cross-speciality services. 65 patients had their immunosupressant therapy adjusted in the TDM service. The pharmacist is gatekeeper for testing and is responsible for optimising therapies (as a non-medical prescriber). The advice sought from the rapid access service was primarily nurse-orientated and the service remains nurse-lead, with pharmacist deputising to maximise resources. In 4 months 142 of 1032 queries were answered by the pharmacist. The MDT reviewed 42 patients on biologics according to the new pathways. The TDM service resulted in a minimum of £60,000 savings for the health economy. 6 of 6 peer-assessors returned overwhelmingly positive reviews of the service and patient feedback was fa. Conclusion Involving the pharmacist in all aspects of the long-term care of patients with IBD enhanced patient safety and standardised treatment and monitoring protocols, whilst individualising therapy. The focus of the MDT shifted to early medicines optimisation, realising considerable cost savings. Interprofessional relationships profited from working closely together / deputising for each other. Embedding pharmaceutical skills into the multidisciplinary team influenced therapeutic decision making, ensuring that services incorporated good medicine management and medicine optimisation principles at conception to guarantee high-quality, compassionate care and strong governance. Disclosure of interest None Declared.</description><subject>Blood levels</subject><subject>Chronic illnesses</subject><subject>Decision making</subject><subject>Disease management</subject><subject>Drug stores</subject><subject>Embedding</subject><subject>Feedback</subject><subject>Immunomodulation</subject><subject>Patients</subject><subject>Therapeutic drug monitoring</subject><issn>0017-5749</issn><issn>1468-3288</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNot0E1OwzAQBWALgUQpXAFFYu0yEzv-WaKqBaRKsChry3Wc1lX-cJwFt-EsnIygsJrN07ynj5B7hBUiE4_HMZ3bmuaABWWglcAVB3ZBFsiFoixX6pIsAFDSQnJ9TW6G4QwASmlckO37_oPmSv98b5qDL8vQHrP-ZGNjnR9TcLbOnI0-C23qsnTyWTPWKZRhcKGvQ2vjV5a8bW7JVWXrwd_93yXZbzf79QvdvT2_rp921MkCaY65A-mtOmgtCtQOUHvBc6cUasW0d06gFoBlZaet1nsplS5QKKwsMs6W5GF-28fuc_RDMudujO3UaHLgjCkJHKeUmFMudsMQfWX6GJppqkEwf2RmJjN_ZGYmMxMZ-wXE2WAb</recordid><startdate>201506</startdate><enddate>201506</enddate><creator>Jones, A St. Clair</creator><creator>Smith, MA</creator><general>BMJ Publishing Group LTD</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>201506</creationdate><title>PTU-289 Embedding pharmaceutical care into the multidisciplinary team</title><author>Jones, A St. Clair ; Smith, MA</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c751-212c07ea8b996519c019e642c8819839ecc619601dfa574aee778951681fa1343</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Blood levels</topic><topic>Chronic illnesses</topic><topic>Decision making</topic><topic>Disease management</topic><topic>Drug stores</topic><topic>Embedding</topic><topic>Feedback</topic><topic>Immunomodulation</topic><topic>Patients</topic><topic>Therapeutic drug monitoring</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jones, A St. Clair</creatorcontrib><creatorcontrib>Smith, MA</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Gut</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jones, A St. Clair</au><au>Smith, MA</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>PTU-289 Embedding pharmaceutical care into the multidisciplinary team</atitle><jtitle>Gut</jtitle><date>2015-06</date><risdate>2015</risdate><volume>64</volume><issue>Suppl 1</issue><spage>A187</spage><epage>A188</epage><pages>A187-A188</pages><issn>0017-5749</issn><eissn>1468-3288</eissn><abstract>Introduction Pharmacists traditionally do not get involved in the long-term management of patients with chronic disease. This service development aimed to integrate pharmacy-lead IBD medication optimisation into the IBD Multi Disciplinary Team (MDT). We report our experience of extending our specialist pharmacist's remit. Method A weekly pharmacist outpatient clinic was established, to initiate immunomodulating drugs and undertake biochemical monitoring. The pharmacist optimised therapy according to blood levels, adverse drug reactions (ADRs) and concordance. Strategic and operational management of the biologics infusion clinic was transferred to the pharmacist. A new blood and therapeutic drug monitoring (TDM) service for immunomodulators and biologics was introduced to optimise therapy decisions. The rapid access (helpline) service was reviewed to see whether the pharmacist could add value. The pharmacist facilitated MDT-approved pathways to initiate and review immunomodulators. A workload and prescription audit was conducted over four months with financial impact assessment. Patient and anonymous colleague feedback was sought. Results In the four months analysed, 14 pharmacist clinics were held, serving 138 patients. 382 patients had blood monitoring, ensuring clinical governance. The biologics infusion clinic expanded to include a cross-speciality services. 65 patients had their immunosupressant therapy adjusted in the TDM service. The pharmacist is gatekeeper for testing and is responsible for optimising therapies (as a non-medical prescriber). The advice sought from the rapid access service was primarily nurse-orientated and the service remains nurse-lead, with pharmacist deputising to maximise resources. In 4 months 142 of 1032 queries were answered by the pharmacist. The MDT reviewed 42 patients on biologics according to the new pathways. The TDM service resulted in a minimum of £60,000 savings for the health economy. 6 of 6 peer-assessors returned overwhelmingly positive reviews of the service and patient feedback was fa. Conclusion Involving the pharmacist in all aspects of the long-term care of patients with IBD enhanced patient safety and standardised treatment and monitoring protocols, whilst individualising therapy. The focus of the MDT shifted to early medicines optimisation, realising considerable cost savings. Interprofessional relationships profited from working closely together / deputising for each other. Embedding pharmaceutical skills into the multidisciplinary team influenced therapeutic decision making, ensuring that services incorporated good medicine management and medicine optimisation principles at conception to guarantee high-quality, compassionate care and strong governance. Disclosure of interest None Declared.</abstract><cop>London</cop><pub>BMJ Publishing Group LTD</pub><doi>10.1136/gutjnl-2015-309861.403</doi></addata></record>
fulltext fulltext
identifier ISSN: 0017-5749
ispartof Gut, 2015-06, Vol.64 (Suppl 1), p.A187-A188
issn 0017-5749
1468-3288
language eng
recordid cdi_proquest_journals_2043387041
source BMJ Journals - NESLi2; PubMed Central
subjects Blood levels
Chronic illnesses
Decision making
Disease management
Drug stores
Embedding
Feedback
Immunomodulation
Patients
Therapeutic drug monitoring
title PTU-289 Embedding pharmaceutical care into the multidisciplinary team
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T22%3A57%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=PTU-289%C2%A0Embedding%20pharmaceutical%20care%20into%20the%20multidisciplinary%20team&rft.jtitle=Gut&rft.au=Jones,%20A%20St.%20Clair&rft.date=2015-06&rft.volume=64&rft.issue=Suppl%201&rft.spage=A187&rft.epage=A188&rft.pages=A187-A188&rft.issn=0017-5749&rft.eissn=1468-3288&rft_id=info:doi/10.1136/gutjnl-2015-309861.403&rft_dat=%3Cproquest_cross%3E2043387041%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2043387041&rft_id=info:pmid/&rfr_iscdi=true